NEW YORK, Oct. 16 – DoubleTwist has licensed its Prophecy database and tools suite to GPC Biotech, the company said on Tuesday.
Financial terms of the agreement were not disclosed.
"DoubleTwist's Prophecy suite gives us comprehensive access to annotated public genome data and effective tools for their use,” Greg Hamm, vice president for bioinformatics at GPC Biotech said in a statement. “We are looking forward to mining this valuable data set.”
DoubleTwist, of Oakland, Calif., recently announced the release of its third-generation Prophecy database, which the company says includes an assembled genome of more than 35 databases onto a single genomic scaffold.
GPC Biotech, based in Munich, Germany, is a genomics- and proteomics-based drug-discovery company focused on drugs in oncology, infectious diseases, and immunology.